Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...
Find MoreOn September 15, the FDA authorized GSK’s oral medication momelotinib, now known as Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis is a disorder where normal bone marrow tissue is slowly substituted by fibrous, scar-like material. It is categorized as a form of chronic leukemia and...
Find MoreMyelofibrosis (MF) is a rare type of bone marrow cancer resulting in abnormal functioning of blood-forming cells and fibres. MF belongs to a group of disorders known as myeloproliferative disorders. This condition results in the widespread scarring of bone marrow leading to anaemia decreased count of platelets, and...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!